Home Decentralization, Automation, and Single-Use Technology – Future of Cell & Gene Therapy Manufacturing

As the biopharmaceutical industry shifts its focus toward cell and gene therapies, the manufacturing landscape presents both opportunities and challenges. While regulatory approvals have enabled the industry to make strides in disease treatment, there is an ongoing need to optimize and streamline manufacturing processes to ensure cost-effective and scalable deployment. The current challenges faced by cell and gene therapy (CGT) manufacturers include challenges associated with delivery system manufacturing, stability, and contamination control. However, disruptive approaches such as decentralized manufacturing, automation, disposable bioreactors, and digitalization of the supply chain are poised to revolutionize the industry.

The adoption of disposable production . . .

Access the full-content and exclusive insights by registering to futurebridge.com.

Benefits to Registered User on FutureBridge

Explore Key trends

Stay on top of your industry related trends and oppotunities.

Access to exclusive content

Get insightful information access without any restrictions.

Trending topics

Learn about fundamental challenges confronted by your industry.

Unrestricted webinar access

Gain access to all upcoming webinars and reply on-demand.

Need a thought partner?

Share your focus area or question to engage with our Analysts through the Business Objectives service.

Submit My Business Objective

Our Clients

Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.